Mizuho raises Tandem Diabetes Care stock price target on Q3 beat
Mizuho raised its price target on Tandem Diabetes Care (TNDM) to $20 from $18, citing Q3 sales beat. Revenue grew 14% YoY to $284M, exceeding estimates. Gross margin improved to 57%, and adjusted EBITDA margin reached 6%. The company maintained its fiscal 2026 guidance but expects slower growth in 2027 due to pharmacy adoption headwinds.
How this was made
The 30-second read
Why it matters
The earnings beat and Mizuho's target raise provide a fresh catalyst for the stock, likely prompting short‑term buying.
Market read
First report of Tandem's Q3 results and analyst target raise, offering actionable insight for traders.
What to watch
Slower pharmacy adoption and potential supply constraints could curb future growth.
Background
Tandem Diabetes Care reported Q3 revenue of $284 million, a 14% YoY increase, beating estimates, with record pump shipments and margin improvement.
Ticker impact
Mizuho raised its price target on Tandem Diabetes Care (TNDM) to $20 from $18 after the company posted a Q3 earnings beat.
upward pressure as the market prices in the higher target and earnings beat.
The price target increase reflects confidence in the recent revenue beat and margin expansion, likely prompting buying interest.
Market effects
Positive earnings and target raise may lift other diabetes‑device makers and related med‑tech stocks.
U.S. small‑cap healthcare sector could see modest gains.
Limited to U.S. investors; no broader macro effect.
Counterpoint
The company remains unprofitable and faces headwinds in 2027; the target raise may be premature.
Key entities
- analystMizuho
Raised price target to $20, Neutral rating.
- companyTandem Diabetes Care
Delivered Q3 earnings beat and margin expansion.
